[ET Net News Agency, 19 June 2018] Sino Biopharmaceutical (01177) said Lidocaine
Cataplasm (Product name "Debaining"), a drug developed by its subsidiary Beijing Tide
Pharmaceutical, has obtained approval for drug registration by the National Drug
Administration of the People's Republic of China.
In addition, the product has obtained a new drug certificate with a four-year monitoring
period. This marks the upcoming official launch of the first topical therapeutic patch in
the field of neuropathic pain in China, which fills the gap in the PRC.
Lidocaine Cataplasm is used to treat postherpetic neuralgia, and is listed as a
first-class recommended drug in clinical guidelines in the United States, Europe, China
and other places. (KL)